Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
Scientific Community
Become a Member | Sign in
Home>News>This Article

A Convenient Way to Screen Hydrogel Stiffness for Stem Cell Applications

Published: Tuesday, August 28, 2012
Last Updated: Tuesday, August 28, 2012
Bookmark and Share
BioTime, Inc. announce the debut of their new Glycosan-branded hydrogel kit for screening the stiffness requirements for growing 3D cell cultures.

Research has shown that in addition to induction factors, the rigidity of the substrate on which cells are grown has a significant influence in the lineage specificity of the cell. By mimicking the cell’s in-vivo environment on a petri dish, the cell has a greater affinity to differentiate into specific cell lines.

glycosan.gifThe HyStem-C Stiffness Sampler Trio Kit contains hyaluronan-based, synthetic extracellular matrices that can conveniently screen for the perfect in-vitro environment for stem cells to proliferate.  The kit contains three hydrogels of defined stiffness to take the guesswork out of choosing the right rigidity.  Like its predecessors, the gels are biocompatible, customizable, and allows for attachment of multiple cell types. The hydrogel is easily prepared by mixing the gel and water (both included in the kit) together. Then the cells are either plated on top or encapsulated in the gel. Current applications include vascular morphogenesis, neurogenesis, and other soft tissue cell cultures. For more information, please visit Glycosan’s website at

BioTime, Inc. is a biotechnology company focused on regenerative medicine. The company develops and markets research products in the field of stem cells and regenerative medicine through its wholly owned subsidiary ReCyte Therapeutics, Inc. The company engages in two areas of biomedical research and product development. Its focus is in the field of regenerative medicine; specifically human embryonic stem cell and induced pluripotent stem cell technology. BioTime was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OncoCyte and Abcodia to Collaborate on Breast Cancer Diagnostic Development
PanC-Dx™ markers to be validated using pre-diagnosis patient serum samples exclusively provided by Abcodia.
Tuesday, September 16, 2014
BioTime Completes Merger of XenneX, Inc. into LifeMap Sciences, Inc.
LifeMap Sciences now holds the exclusive, worldwide licenses to market GeneCards(R) and PanDaTox from Yeda Research and Development Company Ltd.
Monday, May 21, 2012
BioTime to Produce Stem Cells for Research in Muscle Disorders
The company announced that it has elected to market progenitors of muscle stem cells bearing hereditary diseases and will produce the products from five human embryonic stem (hES) cell lines from Reproductive Genetics Institute (RGI).
Tuesday, January 03, 2012
BioTime Announces Appointment of Chief Financial Officer
Peter Garcia will lead the accounting, finance and investor relations functions of the Company, reporting directly to Michael D. West, Ph.D., President and CEO.
Monday, October 10, 2011
BioTime and Embryome Sciences Launch and the International Embryome Initiative
The international collaboration with scientists around the world will create the first systematic map of all the cell types derived from human embryonic stem cells.
Monday, June 30, 2008
Scientific News
Gene Editing Corrects Sickle Cell Mutation
Researchers demonstrate a potential pathway to developing gene-editing treatments for sickle cell disease.
ALS Study Reveals Role of RNA-Binding Proteins
The findings are a significant step forward in validating RNA-based therapy as a treatment for ALS.
Gene Therapy Going Global with Portable Device
Portable 'gene therapy in a box' could make future cancer and HIV cures affordable in developing countries.
RNA-Binding Proteins Role in ALS Revealed
Researchers describe how damage to RNA-binding protein contributes to ALS, isolating a possible therapeutic target.
Genome Engineering Paves Way For Sickle Cell Cure
Researchers from UC Berkeley have used CRISPR-Cas9 gene editing to fix the mutated gene responsible for sickle cell disease.
Preventing Alzheimer's in Mice
Researchers have prevented the Alzheimer’s development in mice by using a virus delivery system to transport a specific gene into the brain.
Link Between Heart and Blood Cells in Early Development Found
Researchers have identifed a key factor in determining the fate of early undifferentiated cells during development.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Scientists Speed Up Muscle Repair
Researchers discovered genetically modified mice were able to support far more regenerative stem cells, for muscle repair, than previously thought.
Nanosensors Could Determine Tumours’ Ability to Remodel Tissue
Researchers design nanosensors that can profile tumours, focusing on protease levels.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos